NCT02540928 - AMG 319 in HPV Positive and Negative HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 3, 2018

Study Completion Date

May 3, 2018

Conditions

Human Papillomavirus (HPV)Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx

Interventions

DRUG

AMG 319 hydrate

DRUG

Placebo

Trial Locations (5)

CH63 4JY

Aintree University Hospital - Clatterbridge Cancer Centre, Liverpool

OX3 7LE

Churchill Hospital, Blenheim H&N Unit, Oxford

BH15 2JB

Poole Hospital, Poole

PO6 3LY

Queen Alexandra Hospital, Department of Oral and Maxillofacial Surgery, Portsmouth

SO16 6YD

Southampton General Hospital, Southampton